EndoAngel
About Us
Making expert-level endoscopy quality accessible to every patient, everywhere.
Company Overview
Company Overview
EndoAngel is developed by a team of AI researchers, gastroenterologists, and medical device engineers dedicated to improving endoscopy outcomes through artificial intelligence.
“Make expert-level endoscopy quality accessible to every patient, everywhere.”
We develop AI-powered computer-aided detection and diagnosis systems for gastrointestinal endoscopy, helping endoscopists detect more lesions and maintain consistent procedure quality.
50+
Partner Hospitals
Worldwide
1,000,000+
Procedures
Assisted
10+
Peer-Reviewed
Publications
2015
Founded in
Wuhan, China
Why EndoAngel
Our Strengths
🏥
Clinical Foundation
- Developed with leading gastroenterology departments
- Validated through rigorous RCTs
- Published in top-tier medical journals
⚡
Technical Excellence
- Real-time AI inference <40ms latency
- Seamless HDMI integration
- Continuous model improvement
🌎
Global Vision
- Serving hospitals across Asia, Europe, Middle East
- Localized distributor support
- Multi-language interface
Certifications & Compliance
Meets the strictest medical device standards globally.
NMPA
Class III
China
CE
European
Conformity
ISO 13485
Quality
Management
GDPR
Compliant
Data Handling
Our Journey
Company History
From startup to global AI endoscopy leader
2015
Company Founded
Wuhan EndoAngel Medical Technology Co., Ltd. established in Wuhan, China.
2017
First Product Launch
EndoAngel colonoscopy AI assistant developed and entered clinical trials.
2019
NMPA Certification
First AI endoscopy product approved in China — NMPA Class III registration.
2020
Lancet Publication
Landmark RCT published in Lancet Gastroenterology & Hepatology.
2021
CE Mark
Obtained European CE Mark certification, opening the international market.
2022
1,000 Hospitals
ENDOANGEL deployed in over 1,000 medical institutions worldwide.
2023
Upper GI & EUS
Upper GI AI Assistant and EUS AI Assistant launched.
2025
50+ SCI Publications
Published more than 50 SCI papers in Gut, Lancet, and Nature subgroups.
Recognition
Honors & Certifications
Scientific Achievements
Scientific Achievements
By February 2025, EndoAngel has carried out scientific research projects with more than 60 medical institutions, publishing more than 50 SCI papers in Gut, Lancet, and Nature subgroups.
- 7 papers in Lancet subgroups
- 2 papers in Nature subgroups
- Highest single IF: 30.9
- Total SCI IF: 496.4
50+
SCI Publications
60+
Research Partners
30.9
Highest IF (single paper)
496
Total SCI Impact Factor
Global Reach
Sales Network
By December 2024, ENDOANGEL has been used in more than 1,000 medical institutions worldwide.
- ✓ Early cancer: 2,230 cases detected
- ✓ Low-grade neoplasia: 63,358 cases
- ✓ Total detections: 152,687 cases
- ✓ Coverage: Asia · Europe · Middle East
1,000+
Medical Institutions
33.63%
Early Detection Rate
1,000+
Medical Institutions
33.63%
Early Detection Rate
152,687
Cases Detected
Asia · Europe
Middle East
Global Coverage
Cooperative Partners
Cooperative Partners
EndoAngel partners with over 1,000 leading medical institutions globally.
Grow With Us
Partner With Us
We are actively expanding our global distributor network.
- Exclusive territory arrangements available
- Comprehensive training and technical support
- Marketing materials and clinical evidence packages
- Ongoing product updates and new module access
What We Provide
🎓 Training
Full onboarding for clinical and technical staff
📄 Clinical Evidence
Published RCT data and marketing materials
🔧 Technical Support
Installation and ongoing maintenance
🔄 Product Updates
Regular AI model improvements and new features